Aptevo Therapeutics (APVO) Competitors $1.76 +0.05 (+2.92%) Closing price 04:00 PM EasternExtended Trading$1.72 -0.03 (-1.99%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APVO vs. FNCH, CTXR, PRPH, THAR, ASBP, NAII, CLRB, EDSA, IXHL, and ABPShould you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Finch Therapeutics Group (FNCH), Citius Pharmaceuticals (CTXR), ProPhase Labs (PRPH), Tharimmune (THAR), Aspire Biopharma (ASBP), Natural Alternatives International (NAII), Cellectar Biosciences (CLRB), Edesa Biotech (EDSA), Incannex Healthcare (IXHL), and Abpro (ABP). These companies are all part of the "pharmaceutical products" industry. Aptevo Therapeutics vs. Its Competitors Finch Therapeutics Group Citius Pharmaceuticals ProPhase Labs Tharimmune Aspire Biopharma Natural Alternatives International Cellectar Biosciences Edesa Biotech Incannex Healthcare Abpro Finch Therapeutics Group (NASDAQ:FNCH) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations. Do analysts recommend FNCH or APVO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Do institutionals and insiders have more ownership in FNCH or APVO? 21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 0.0% of Aptevo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, FNCH or APVO? Finch Therapeutics Group has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.87, suggesting that its stock price is 487% more volatile than the S&P 500. Does the media prefer FNCH or APVO? In the previous week, Aptevo Therapeutics had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Aptevo Therapeutics and 1 mentions for Finch Therapeutics Group. Aptevo Therapeutics' average media sentiment score of 0.72 beat Finch Therapeutics Group's score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Finch Therapeutics Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aptevo Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, FNCH or APVO? Aptevo Therapeutics has higher revenue and earnings than Finch Therapeutics Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.38Aptevo Therapeutics$3.11M1.86-$24.13MN/AN/A Is FNCH or APVO more profitable? Finch Therapeutics Group's return on equity of -69.14% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Finch Therapeutics GroupN/A -69.14% -26.92% Aptevo Therapeutics N/A -675.52%-175.68% SummaryAptevo Therapeutics beats Finch Therapeutics Group on 7 of the 11 factors compared between the two stocks. Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APVO vs. The Competition Export to ExcelMetricAptevo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.62M$3.37B$6.14B$10.65BDividend YieldN/A2.29%5.66%4.70%P/E RatioN/A21.3485.8427.65Price / Sales1.86488.69626.36141.34Price / CashN/A47.1938.3262.20Price / Book0.0310.4313.066.79Net Income-$24.13M-$52.40M$3.30B$275.88M7 Day Performance21.38%6.36%4.81%2.64%1 Month Performance15.03%16.14%9.99%9.13%1 Year Performance-99.96%33.90%85.28%35.89% Aptevo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APVOAptevo Therapeutics1.5595 of 5 stars$1.76+2.9%N/A-100.0%$5.62M$3.11M0.0050Analyst ForecastFNCHFinch Therapeutics Group0.7706 of 5 stars$12.25+0.3%N/A+5.2%$19.67MN/A-1.39190CTXRCitius Pharmaceuticals2.7112 of 5 stars$1.18+2.6%$53.00+4,391.5%-86.8%$19.56MN/A0.0020Positive NewsAnalyst ForecastHigh Trading VolumePRPHProPhase Labs0.4041 of 5 stars$0.44-1.1%N/A-77.8%$18.39M$5.59M-0.35130Analyst ForecastGap UpTHARTharimmune2.5079 of 5 stars$2.90-4.0%$17.00+486.2%+56.7%$17.83MN/A-0.482News CoverageAnalyst ForecastASBPAspire BiopharmaN/A$0.31-13.0%N/AN/A$17.80MN/A0.00N/AAnalyst ForecastGap DownNAIINatural Alternatives International1.3159 of 5 stars$2.91+1.0%N/A-40.2%$17.79M$125.48M-1.28290Analyst ForecastCLRBCellectar Biosciences2.399 of 5 stars$5.41-2.0%$375.00+6,831.6%-92.5%$17.62MN/A-0.2710Analyst ForecastEDSAEdesa Biotech3.2524 of 5 stars$2.45-1.6%$5.00+104.1%-36.2%$17.52MN/A-1.8620Positive NewsAnalyst ForecastHigh Trading VolumeIXHLIncannex Healthcare0.7637 of 5 stars$0.52-12.8%N/A-72.3%$17.51M$98K-0.433News CoverageAnalyst ForecastShort Interest ↓High Trading VolumeABPAbpro3.3081 of 5 stars$0.26+17.9%$4.00+1,457.0%N/A$17.47M$183K0.0015Analyst ForecastGap UpHigh Trading Volume Related Companies and Tools Related Companies FNCH Alternatives CTXR Alternatives PRPH Alternatives THAR Alternatives ASBP Alternatives NAII Alternatives CLRB Alternatives EDSA Alternatives IXHL Alternatives ABP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APVO) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
